AAPL 192.4902 0.7591% MSFT 429.38 0.9498% GOOG 179.04 0.325% GOOGL 177.45 0.2996% AMZN 182.02 -0.8282% NVDA 947.4001 -0.0422% META 464.53 -0.9193% TSLA 186.0554 6.3478% TSM 153.42 -0.0847% LLY 803.85 2.6392% V 276.17 -0.8509% AVGO 1399.41 -1.0339% JPM 198.68 1.585% UNH 522.2967 0.9796% NVO 134.5401 1.2265% WMT 64.9 1.1218% LVMUY 166.815 -1.2052% XOM 118.03 -0.5393% LVMHF 846.034 0.1224% MA 457.885 -0.3862%

Khiron Life Sciences Corp

Healthcare US KHRNF


Last update at 2024-05-20T13:30:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Income before tax -33.59400M -23.94991M -36.35503M -19.72796M -4.53529M
Minority interest - - - 0.00000M 0.00000M
Net income -33.12900M -24.03889M -36.37778M -19.80654M -4.53529M
Selling general administrative 23.99M 28.41M 35.91M 20.19M 3.31M
Selling and marketing expenses - - - - -
Gross profit 6.37M 7.01M 2.44M 0.30M 0.00000M
Reconciled depreciation 1.11M 1.17M 0.94M 0.34M -
Ebit -20.02600M -23.60499M -35.97963M -18.62518M -4.51750M
Ebitda -32.03400M -22.43750M -36.64132M -19.55841M -
Depreciation and amortization - - - - -
Non operating income net other - - - 0.00000M 0.00000M
Operating income -19.78700M -23.60499M -37.57985M -19.89633M -4.51750M
Other operating expenses - - - 0.00000M 0.00000M
Interest expense 0.45M 0.00000M 0.00000M 0.00000M 0.00000M
Tax provision -0.46500M 0.09M 0.02M 0.08M -
Interest income - - - - -
Net interest income -0.44500M - - - -
Extraordinary items - - - 0.00000M 0.00000M
Non recurring - - - 0.00000M 0.00000M
Other items - - - 0.00000M 0.00000M
Income tax expense -0.46500M 0.09M 0.02M 0.08M 0.00000M
Total revenue 12.79M 8.02M 9.58M 0.89M 0.00000M
Total operating expenses 32.58M 31.62M 47.16M 20.79M 4.52M
Cost of revenue 6.42M 1.01M 7.15M 0.59M 0.00000M
Total other income expense net -13.36100M -0.34492M 1.22M 0.17M -0.01779M
Discontinued operations - - - 0.00000M 0.00000M
Net income from continuing ops -33.12900M -24.03889M -36.37778M -19.80654M -4.53529M
Net income applicable to common shares -33.12900M -24.03889M -36.37778M -19.80654M -4.53529M
Preferred stock and other adjustments - - - 0.00000M 0.00000M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Total assets 42.27M 73.18M 81.91M 40.35M 2.90M
Intangible assets 0.87M 15.13M 15.55M 2.01M 0.00097M
Earning assets - - - - -
Other current assets - 14.28M 1.97M 0.08M 0.00000M
Total liab 8.95M 9.95M 11.87M 14.81M 0.70M
Total stockholder equity 33.33M 63.23M 70.04M 25.54M 2.19M
Deferred long term liab - - - 0.00000M 0.00000M
Other current liab 1.89M - - 0.18M 0.21M
Common stock 146.45M 137.08M 121.29M 39.83M 4.29M
Capital stock 146.45M 137.08M 121.29M 39.83M -
Retained earnings -116.81200M -83.68299M -59.96373M -23.58595M -3.77941M
Other liab 0.52M 0.90M 0.89M 5.86M 0.00000M
Good will 4.08M 4.11M 4.35M 4.64M 0.00000M
Other assets - - 1.34M 0.15M 0.00000M
Cash 8.92M 8.17M 9.17M 14.93M 1.81M
Cash and equivalents - - - - -
Total current liabilities 7.72M 7.34M 8.44M 6.60M 0.70M
Current deferred revenue - - - - -
Net debt - - - - -
Short term debt - - - 0.00000M 0.00000M
Short long term debt 1.52M 1.08M 1.01M 0.16M 0.00000M
Short long term debt total - - - - -
Other stockholder equity 3.69M 9.83M 8.71M 9.30M 1.68M
Property plant equipment 13.56M 17.52M 15.86M 9.62M 0.24M
Total current assets 23.77M 36.42M 44.81M 23.93M 2.65M
Long term investments - - - 0.00000M 0.00000M
Net tangible assets 28.39M 43.98M 50.14M 18.90M 2.19M
Short term investments - 0.00000M 27.56M 3.95M 0.00000M
Net receivables 2.88M 4.58M 4.24M 4.17M 0.29M
Long term debt 0.70M 1.71M 2.55M 2.35M 0.00000M
Inventory 9.45M 8.34M 0.96M 0.24M 0.00000M
Accounts payable 4.31M 6.26M 7.43M 6.44M 0.45M
Total permanent equity - - - 0.00000M 0.00000M
Noncontrolling interest in consolidated entity - - - 0.00000M 0.00000M
Temporary equity redeemable noncontrolling interests - - - 0.00000M 0.00000M
Accumulated other comprehensive income - - - 0.00000M 0.00000M
Additional paid in capital - - - 0.00000M 0.00000M
Common stock total equity - - - 0.00000M 0.00000M
Preferred stock total equity - - - 0.00000M 0.00000M
Retained earnings total equity - - - 0.00000M 0.00000M
Treasury stock - - - 0.00000M 0.00000M
Accumulated amortization - - - 0.00000M 0.00000M
Non currrent assets other - - 37.10M 16.42M 0.00000M
Deferred long term asset charges - - - 0.00000M 0.00000M
Non current assets total 18.50M 36.76M 37.10M 16.42M 0.00000M
Capital lease obligations - - - 0.00000M 0.00000M
Long term debt total - - - 0.00000M 0.00000M
Breakdown 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Type yearly yearly yearly yearly yearly
Date 2021-12-31 2020-12-31 2019-12-31 2018-12-31 2017-12-31
Investments -2.08600M 27.56M -23.05105M -3.94955M -3.94955M
Change to liabilities -2.83200M -1.86119M 0.85M 0.67M 0.85M
Total cashflows from investing activities -2.08600M 24.87M -31.97643M -9.21997M -0.29034M
Net borrowings -0.10700M -0.55519M -1.27270M 11.59M 11.59M
Total cash from financing activities 10.89M 12.17M 57.00M 37.59M 5.41M
Change to operating activities -0.36000M 1.39M -1.94902M 0.00536M -0.08581M
Net income -33.12900M -24.03889M -36.37778M -19.80654M -4.53529M
Change in cash -12.72600M 12.30M -5.66884M 13.20M 2.17M
Begin period cash flow 21.65M 9.34M 15.01M 1.81M 0.00496M
End period cash flow 8.92M 21.65M 9.34M 15.01M 1.81M
Total cash from operating activities -20.40000M -24.53235M -30.07485M -14.77391M -2.90955M
Issuance of capital stock 11.00M 12.94M 53.14M 0.91M -
Depreciation 1.11M 1.17M 0.94M 0.34M 0.00008M
Other cashflows from investing activities - - - 0.00000M 0.00000M
Dividends paid - - - 0.00000M 0.00000M
Change to inventory -1.44000M -2.06976M -0.70045M -0.18122M -0.18122M
Change to account receivables 2.31M 0.61M -1.38182M 0.83M -0.34431M
Sale purchase of stock 0.00000M -0.21239M - 0.00000M 0.00001M
Other cashflows from financing activities - 0.58M 2.69M 2.69M 2.69M
Change to netincome 13.94M 0.28M 8.55M 3.37M 1.21M
Capital expenditures 1.74M 2.69M 6.09M 3.83M 0.29M
Change receivables - - - 0.00000M 0.00000M
Cash flows other operating - - - 0.00000M 0.00000M
Exchange rate changes - - - 0.00000M 0.00000M
Cash and cash equivalents changes - - - 0.00000M 0.00000M
Change in working capital -2.32700M -1.93891M -3.18238M 1.33M -
Stock based compensation 2.32M 5.72M 9.37M - -
Other non cash items -1.08200M -5.52745M -0.84705M - -
Free cash flow -22.14400M -27.22550M -36.16960M -18.59974M -


  • Previous Close 0.009
  • Market Cap7.01M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-16.40602M
  • Revenue TTM16.14M
  • Revenue Per Share TTM0.09
  • Gross Profit TTM 6.37M
  • Diluted EPS TTM-0.13

Peer Comparison

Sector: Healthcare Industry: Drug Manufacturers - Specialty & Generic

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Khiron Life Sciences Corp
- -% 0.009 - - 0.43 0.05 0.10 -0.0546
Zoetis Inc
-1.65 0.95% 172.74 40.18 30.96 10.67 17.60 11.27 26.18
Merck KGaA ADR
-0.19 0.53% 35.92 21.25 14.93 3.10 2.14 3.60 12.98
MERCK Kommanditgesellschaft auf Aktien
-4.75 2.60% 178.25 21.73 14.95 3.16 2.15 3.56 12.82
Takeda Pharmaceutical Co Ltd ADR
-0.09 0.68% 13.19 32.67 11.53 0.01 0.87 0.02 0.07

Reports Covered

Stock Research & News


Khiron Life Sciences Corp. operates as an integrated medical and cannabis company in Latin America and Europe. It operates through Health Services, Medical Cannabis Products, and Wellbeing Products segments. The company focuses on the cultivation, production, distribution, and export of tetrahydrocannabinol and cannabidiol (CBD) medical cannabis. It also operates a network of health centers and satellite clinics under the ILANS and Zerenia brands; develops CBD-based cosmeceutical products under the Kuida brand name; and operates Zerenia clinic in Medellin and Peru. Khiron Life Sciences Corp. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Khiron Life Sciences Corp

500 Burrard Street, Vancouver, BC, Canada, V6C 2B5

Key Executives

Name Title Year Born
Dr. Alvaro Francisco Torres Co-Founder, CEO & Director 1979
Ms. Franziska Katterbach Pres of Khiron Europe NA
Mr. Swapan Kakumanu ACA, ACWA, CGA Corp. Sec. 1970
Ms. Helen Bellwood A.C.A. Interim Chief Financial Officer NA
Mr. Manuel Buendia VP of Operations NA
Mr. Luis Chavez Country Mang. of Mexico NA
Mr. Marco Algorta Country Mang. of Uruguay NA
Mr. Juan Diego Alvarez VP of Regulations 1985

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).